Journal article
Prodrugs as self-assembled hydrogels: a new paradigm for biomaterials
Current opinion in biotechnology, Vol.24(6), pp.1174-1182
12/2013
DOI: 10.1016/j.copbio.2013.02.006
PMID: 23465753
Abstract
[Display omitted]
► Development of prodrug-based self-assembled hydrogels as a new class of biomaterials. ► Design of prodrugs that can self-assemble to form hydrogels. ► These hydrogels overcome limitations such as low-drug loading and burst release of drugs. ► Locally injectable self-assembled hydrogels exhibit potential as effective therapeutics.
Prodrug-based self-assembled hydrogels represent a new class of active biomaterials that can be harnessed for medical applications, in particular the design of stimuli responsive drug delivery devices. In this approach, a promoiety is chemically conjugated to a known-drug to generate an amphiphilic prodrug that is capable of forming self-assembled hydrogels. Prodrug-based self-assembled hydrogels are advantageous as they alter the solubility of the drug, enhance drug loading, and eliminate the use of harmful excipients. In addition, self-assembled prodrug hydrogels can be designed to undergo controlled drug release or tailored degradation in response to biological cues. Herein we review the development of prodrug-based self-assembled hydrogels as an emerging class of biomaterials that overcome several common limitations encountered in conventional drug delivery.
Details
- Title: Subtitle
- Prodrugs as self-assembled hydrogels: a new paradigm for biomaterials
- Creators
- Praveen Kumar Vemula - Institute for Stem Cell Biology and Regenerative Medicine (inStem), National Centre for Biological Sciences Campus, UAS-GKVK Post, Bellary Road, Bangalore 560065, IndiaNikken Wiradharma - Division of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Harvard-MIT Division of Health Sciences and Technology, 65 Landsdowne Street, Cambridge, MA 02139, USAJames A Ankrum - Division of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Harvard-MIT Division of Health Sciences and Technology, 65 Landsdowne Street, Cambridge, MA 02139, USAOscar R Miranda - Division of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Harvard-MIT Division of Health Sciences and Technology, 65 Landsdowne Street, Cambridge, MA 02139, USAGeorge John - Department of Chemistry, The City University of New York and the Institute of Macromolecular Assemblies, New York, NY 10031, USAJeffrey M Karp - Division of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Harvard-MIT Division of Health Sciences and Technology, 65 Landsdowne Street, Cambridge, MA 02139, USA
- Resource Type
- Journal article
- Publication Details
- Current opinion in biotechnology, Vol.24(6), pp.1174-1182
- Publisher
- Elsevier Ltd
- DOI
- 10.1016/j.copbio.2013.02.006
- PMID
- 23465753
- ISSN
- 0958-1669
- eISSN
- 1879-0429
- Grant note
- name: Department of Biotechnology, India for Ramalingaswami Re-entry Fellowship; name: Beta Cell Biology Consortium; name: Hugh Hampton Young Memorial Fund; DOI: 10.13039/100012131, name: Brain Science Foundation; name: NSF
- Language
- English
- Date published
- 12/2013
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering
- Record Identifier
- 9984000924402771
Metrics
37 Record Views